MoonLake Immunotherapeutics

US · MLTX #3305 by market cap Listed 2020

10.77 -0.18 -1.64%

Live - 5344 symbols - heartbeat 127s ago · 2026-10-08 08:42

Pre-market 10.75 -0.19%

After-hours 10.96 +1.76%

Market cap: 916.60M
P/E (TTM): -2.80
P/B: 2.14
EPS: -3.53
Div yield: 0.00%
52W pos: 14%

Reader sentiment Are you bullish or bearish on MLTX?

Anonymous reader poll. Unscientific, not investment advice.

About MoonLake Immunotherapeutics

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

CEO: Dr. Jorge Santos da Silva
Employees: 130
Headquarters: Zug, Zug, Switzerland
Fiscal year end: 12-31
Website: moonlaketx.com

Company profile

Exchange: US
Symbol: MLTX
Market-cap rank: #3305
Listing date: 2020-10-20
Market cap: 916.60M
Float cap: 597.39M
Shares out: 85.11M
Float shares: 55.47M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 08:42:36 · For reference only, not investment advice and not tailored to your situation.